Allophycocyanin

Other Names

Allophycocyanin BAPCphycobiliprotein

Synopsis

Allophycocyanin: A Comprehensive Reference Article

1. Identity, Chemical Names, and Natural Sources

1.1 Nomenclature and Etymology

Allophycocyanin (abbreviated APC) derives its name from the Greek: ἄλλος (allos) meaning "other," φύκος (phykos) meaning "alga," and κυανός (kyanos) meaning "blue" — thus, literally "other algal blue protein." It belongs to the light-harvesting phycobiliprotein family, along with phycocyanin, phycoerythrin, and phycoerythrocyanin. In the scientific literature it is consistently abbreviated as APC, and in flow cytometry contexts it is often denoted simply as APC. In flow cytometry, it is often abbreviated APC.

1.2 Taxonomic and Biological Sources

Allophycocyanin is categorized as a phycobiliprotein, a class of water-soluble pigments harvested primarily from cyanobacteria (blue-green algae) and red algae. Allophycocyanin absorbs and emits red light (650 and 660 nm max, respectively), and is readily found in cyanobacteria (also called blue-green algae) and red algae. Among cyanobacteria, the commercially dominant source is Arthrospira platensis (commonly marketed as Spirulina), though APC has also been isolated from organisms such as Phormidium sp., Thermosynechococcus elongatus, Aphanizomenon flos-aquae, and various species of the class Rhodophyta (red algae).

Arthrospira is a blue-green photosynthetic filamentous alga that contains phycobiliprotein pigments — phycocyanin (PC), phycoerythrin, and allophycocyanin — along with 15–25% carbohydrates, 18% essential fatty acids, 55–70% proteins, vitamins, and minerals. Phycocyanin, allophycocyanin, and phycoerythrin pigments are abundant in cyanobacteria and form up to 20% of its total dry weight.

1.3 Optical and Spectral Identity

The main phycobiliproteins are blue phycocyanin (absorption maximum 620–625 nm) and allophycocyanin (650 nm), and the red phycoerythrin (565 nm). APC is spectrally distinct from the more abundant C-phycocyanin: allophycocyanin absorbs and emits at longer wavelengths than phycocyanin C or phycocyanin R. These differences are visible to the naked eye — phycocyanin is bright blue, while allophycocyanin is more of a blue-green. In an analytical context, these spectral variations allow the two proteins to be measured separately using spectrophotometry, a preferred method for their quantification in plant extracts, particularly those derived from spirulina.

2. Chemical Structure and Composition

2.1 Protein Architecture

Allophycocyanin is composed of two different subunits (α and β), in which each subunit has one phycocyanobilin (PCB) chromophore. The subunit structure for APC has been determined as (αβ)₃. The molecular weight of APC is 105,000 daltons. This trimeric quaternary arrangement is essential for full spectral and biological activity: this oligomeric state is necessary to provide the specific conformation and relative location of the chromophores to present the typical absorption and emission spectra of APC with λmax Abs = 651 nm and λmax Em = 660 nm.

Phycocyanobilin (PCB) chromophores, covalently bound to conserved Cys residues of α- and β-subunits of APC, are responsible for solar energy absorption from phycocyanin and for transfer to the photosynthetic apparatus. In known APC structures, heterodimers of α- and β-subunits (known as αβ monomers) assemble as trimer or hexamer.

2.2 The Chromophore: Phycocyanobilin

The light-absorbing property is conferred by the chromophore, a linear tetrapyrrole structure known as phycocyanobilin, which is covalently attached to the protein subunits. The protein component acts as a scaffold, holding the chromophore in a specific conformation that determines its vibrant color and fluorescent characteristics. Each subunit contains a phycocyanobilin molecule synthesized by heme oxygenase 1 and phycocyanobilin oxidoreductase enzymes, bound to cysteine 82 by a heterodimeric lyase S/U.

Phycobiliproteins are hydrophilic compounds composed of a protein structure and chromophores called phycobilin. These are water-soluble proteins with open-chain tetrapyrroles as chromophores. The open-chain tetrapyrrole structure of phycocyanobilin is chemically related to mammalian bilirubin and biliverdin: phycocyanobilin (PCB), the covalently bound chromophore of the cyanobacterial protein C-phycocyanin (CPC), is recognized as a bioactive molecule with neuroprotective and anti-inflammatory properties.

2.3 Classification Within the Phycobiliprotein Family

There are four types of phycobiliproteins: phycoerythrin, phycocyanin, phycoerythrocyanin, and allophycocyanin, although the most common and studied one is phycocyanin. Within the phycobilisome, APC occupies a structurally central position: allophycocyanin (APC) is the phycobiliprotein always found in the PBS core complex. It is a structural component of the phycobilisome, the large, antenna-like complex responsible for capturing light energy during photosynthesis. The phycobilisome transfers harvested energy directionally to photosynthetic reaction centers, and APC occupies the innermost (core) portion of this antenna, positioned closest to the thylakoid membrane.

All phycobiliproteins are water-soluble and therefore cannot exist within the membrane like carotenoids, but aggregate, forming clusters that adhere to the membrane called phycobilisomes.

3. Occurrence in Nature: Biological Role

Cyanobacteria and red algae use light-harvesting pigments bound by proteins to capture solar radiation and to channel excitation energy into their reaction centres. In most cyanobacteria, a multi-megadalton soluble structure known as the phycobilisome is a major light-harvesting system. Within this structure, energy flows from phycoerythrin (the outermost rods) through phycocyanin, and finally to allophycocyanin in the core, which then transfers excitation energy to chlorophyll a in the photosynthetic reaction centers.

Being oxygenic phototrophic bacteria, cyanobacteria contain both type-1 and type-2 reaction centers, or photosystems, with a unique "phycobilisome" antenna network that feeds these reaction centers. Unlike plants and green algae, this special phycobilisome consists of 3–7 MDa large multimeric assemblies that associate with the surface of the chloroplast thylakoid membrane. The phycobilisome supplies excitation energy to both reaction centers by forming a megacomplex. Each phycobilisome is built of many units of chromophore-binding phycobiliproteins — phycocyanin, phycoerythrin, and allophycocyanin — and non-chromophore-binding linker proteins.

4. Historical and Traditional Use

4.1 Mesoamerican Cultures

As early as the 16th century, people living near alkaline lakes used Spirulina as a dietary supplement. The Aztecs and other Mesoamericans used it as a food source in Mexico. As described by one of Hernán Cortés' soldiers, algae were harvested at Lake Texcoco and turned into cakes called "tecuitlatl." Historians believe that the Aztecs harvested spirulina from Lake Texcoco around the 14th–16th centuries. They called it "tecuitlatl," which means "fecal stone" in Nahuatl, and used it as a nutrient-rich food source. These cakes constituted a significant nutritional supplement within the Aztec diet.

It is important to note that the Aztecs and other Mesoamerican peoples did not isolate or identify allophycocyanin as a distinct compound — they consumed whole cyanobacterial biomass containing the full spectrum of phycobiliproteins, including APC, as part of an integrated food source. The attribution of specific phytochemical effects to APC specifically is a modern scientific development.

4.2 Central African Traditions

Historically, spirulina has been used as food by the Kanembu ethnic group in the Lake Chad region of the Republic of Chad, to make and sell dried bread called "dihe." After being rediscovered by a European scientific mission in Chad, this traditional food gained popularity in the human health food industry around the world. In 1940, a French botanist named Pierre Dangeard reported on the Kanembu people of Chad using spirulina as food. However, it was not until the 1960s that scientists began to further study this algae. Communities in the Lake Chad region have used spirulina-derived foods for centuries, incorporating the dried cakes into stews and other traditional dishes as a dense protein source.

4.3 Modern Recognition and Commercial Development

Due to its high nutrient content, Spirulina was recognized as a "wonderful future food source" by the International Association of Applied Microbiology in 1967, and later by the United Nations World Food Conference in 1974 and then by the World Health Organization in 1996 as the "best food for the future." This recognition catalyzed industrial cultivation and the commercial extraction of phycobiliproteins, including allophycocyanin. Spirulina is currently the leading microalgae species, with an annual production of about 10,000 tons, mainly produced in China (~66% of total world production).

5. Key Constituents and Active Compounds

5.1 The Phycocyanobilin Chromophore as the Primary Bioactive Unit

PCB is a pigment protein essential for capturing and sensing light in phycocyanin (PC). As an effective antioxidant, anti-inflammatory agent, and anti-cancer agent, PC has been used to treat a variety of diseases by scavenging reactive oxygen species, such as cataracts, nonalcoholic fatty liver, and degenerative diseases. The beneficial biological activities of PC are attributed to the covalently linked chromophore PCB, which usually covalently binds to the apolipoprotein of PC and is part of the biological functions of PC.

Research into recombinant APC has helped delineate the respective contributions of the apoprotein versus the chromophore: the chromophore was thought to be mainly responsible for the antioxidant activity, and the apoprotein supported a local protein environment that gave rise to the conformation of chromophores.

5.2 Relationship to Mammalian Bilirubin Biology

PCB can be obtained through two complementary approaches: extraction from cyanobacterial biomass, where it remains covalently bound to CPC, and heterologous biosynthesis in Escherichia coli, which enables production of free PCB as a high-purity, scalable linear tetrapyrrole suitable for translational applications. This structural similarity to bilirubin — a known endogenous antioxidant in mammals — has been hypothesized to underlie some of the molecule's observed cytoprotective effects, though the precise mechanisms continue to be investigated.

6. Mechanisms of Action

6.1 Antioxidant Mechanisms

Several bioactivities have been associated with phycobiliproteins, such as antioxidant, antiviral, antimicrobial, and anti-inflammatory properties. Studies indicate that allophycocyanin and related phycobiliproteins possess antioxidant capabilities, neutralizing damaging free radicals. The phycocyanobilin chromophore, as an open-chain tetrapyrrole, can donate electrons and quench reactive oxygen species (ROS) directly. C-phycocyanin scavenges hydrogen peroxide, a type of ROS species, from the inside of astrocytes, reducing oxidative stress.

6.2 Anti-Inflammatory Mechanisms

The mechanisms of action of phycocyanin are relative to enzymatic activity (iNOS, COX, and MPO), inhibition of nuclear factor transcriptions (NF-κB), and cytokines (TNF-α, IL-6, and IFN-γ). These mechanisms apply to the phycobiliprotein family broadly, with phycocyanin being the most extensively studied member. Allophycocyanin shares the same phycocyanobilin chromophore and has been demonstrated to exhibit related inflammatory modulation in model systems.

6.3 Longevity and Stress-Response Pathways

The allophycocyanin (APC) protein purified from Phormidium sp. A09DM was investigated for its in vivo antioxidant and anti-aging potential in Caenorhabditis elegans. An increased mean lifespan of APC-treated (100 μg/ml) worms (wild type) was observed from 16 ± 0.2 days (control) to 20 ± 0.1 days (treated). APC-treated worms also showed improved physiological markers of aging such as the rate of pharyngeal pumping and higher rate of survival against oxidative and thermal stress. Furthermore, APC was found to moderate the expression of human amyloid beta (Aβ1–42) as well as associated Aβ-induced paralysis in transgenic C. elegans CL4176 upon increase in temperature.

RNA interference (RNAi)-mediated studies revealed the dependence of downstream regulator daf-16, independent of stress-induced resistance gene skn-1 in APC-treated C. elegans. The daf-16 gene is the worm ortholog of mammalian FOXO transcription factors, which are central regulators of cellular stress responses, autophagy, and lifespan. This mechanistic finding suggests APC may engage conserved insulin/IGF-1 signaling pathways to promote longevity, though this has not yet been demonstrated in mammals or humans.

6.4 Photosensitizer Applications

Phycobiliproteins have been used as fluorescent markers and also for photodynamic therapy of cancer for their antioxidant, anti-inflammatory, and antitumor properties. Phycocyanin shows a wide range of pharmacological effects, with anti-oxidation, anti-cancer, anti-inflammatory activity, photo-induced cytotoxicity, and stimulating the immune system. Phycocyanin could improve the phototoxicity of MWNT-CS-PC and also reduce the cytotoxicity of the carbon nanotube complex on normal cells. It is essential that MWNT-CS-PC conjugate tumor-associated antigen to enhance the targeting ability, so MWNT-CS-PC will possess high potential for photodynamic therapy of cancer. These applications, however, remain at the experimental stage for APC specifically.

7. Scientific Evidence by Area of Use

Important note on evidence framing: The vast majority of published research on the bioactivities of allophycocyanin has been conducted either in vitro (cell-based models) or in simple animal model organisms such as C. elegans. Most human clinical evidence relates to Spirulina as a whole-biomass supplement — which contains APC alongside C-phycocyanin, phycoerythrin, proteins, fatty acids, vitamins, and minerals — making it impossible to attribute observed effects to APC alone. Purified APC-specific human clinical trials have not been identified in the available peer-reviewed literature. Evidence characterization below reflects these limitations explicitly.

7.1 Antioxidant Activity

In vitro / preclinical evidence: The antioxidant capacity of phycobiliproteins, including APC, is well-established in cell-free and cell-based assays. In one study, apo-allophycocyanin (apo-APC) and its protomeric unit αAPC and βAPC subunits were expressed in E. coli as fusion proteins, and their antioxidant activities were evaluated. This research helped demonstrate that the apoprotein itself — not just the chromophore — contributes to radical-scavenging capacity, though the chromophore is considered the primary locus of activity.

Human evidence: Limited clinical studies suggest antioxidant effects of spirulina, but clinical importance has not been demonstrated. In one small clinical study, spirulina showed no effect on plasma antioxidant status. Because these trials studied whole Spirulina biomass, not isolated APC, no conclusion about APC-specific antioxidant effects in humans can be drawn from them.

Evidence strength: Preclinical (in vitro and animal) evidence is consistent; human evidence is limited, indirect, and inconclusive for APC specifically.

7.2 Anti-Inflammatory Activity

In vitro / preclinical: Phycocyanin is an active substance extracted from algae; it has outstanding antioxidant and anti-inflammatory activities, and can effectively inhibit various diseases caused by inflammation. This review systematically summarizes recent applications of phycocyanin against various inflammatory diseases in lung, liver, cardiovascular, and cerebrovascular systems. APC is co-extracted with C-phycocyanin in most preparations and shares the PCB chromophore, which underlies these anti-inflammatory effects in preclinical models.

Human evidence: Spirulina exerted its greatest and most significant effect on body fat reduction (Hedges' g = −0.811, P < 0.001). Other notable and statistically significant benefits included reductions in total cholesterol, triglycerides, and LDL (all Hedges' g = −0.600, P = 0.001). An umbrella review of meta-analyses of RCTs on Spirulina supplementation found effects across cardiometabolic outcomes, though the role of APC specifically within the whole-biomass supplement cannot be isolated from these findings.

Evidence strength: Preclinical anti-inflammatory evidence for phycobiliproteins broadly (including APC) is substantial. Human evidence is limited to Spirulina biomass studies and cannot be attributed specifically to APC.

7.3 Cardiovascular and Lipid Effects

Great attention and extensive studies have been devoted to evaluating therapeutic benefits of Spirulina on an array of diseased conditions including hypercholesterolemia, hyperglycerolemia, cardiovascular diseases, inflammatory diseases, cancer, and viral infections. The cardiovascular benefits of Spirulina are primarily the result of its hypolipidemic, antioxidant, and anti-inflammatory activities. Data from preclinical studies with various animal models consistently demonstrate the hypolipidemic activity of Spirulina. Although differences in study design, sample size, and patient conditions result in minor inconsistency in response to Spirulina supplementation, the findings from human clinical trials are largely consistent with the hypolipidemic effects observed in the preclinical studies.

However, most of the human clinical trials suffer from limited sample size and some from poor experimental design. The antioxidant and/or anti-inflammatory activities of Spirulina were demonstrated in a large number of preclinical studies. However, a limited number of clinical trials have been carried out so far to confirm such activities in humans.

Spirulina, a cyanobacterium rich in essential nutrients, emerges as a promising dietary intervention in addressing cardiometabolic risk factors. Multiple clinical trials showed consistent benefits in reducing body weight, enhancing lipid profiles, and improving inflammation markers and glucose metabolism. Spirulina's composition of phycocyanin, gamma-linolenic acid, B vitamins, and powerful antioxidants are the reason for these positive outcomes. The contribution of APC specifically to these cardiovascular effects has not been studied in isolation.

Evidence strength: Moderate, but attributable to whole Spirulina biomass, not isolated APC. Larger, better-designed RCTs are needed.

7.4 Immunomodulation

In a randomized, double-blind placebo-controlled trial, individuals with allergic rhinitis were fed daily either with placebo or Spirulina for 12 weeks. Peripheral blood mononuclear cells were isolated before and after the Spirulina feeding and levels of cytokines (interleukin-4 (IL-4), interferon-γ (IFN-γ), and interleukin-2) were measured. The study showed that a high dose of Spirulina significantly reduced IL-4 levels by 32%, demonstrating the protective effects of this microalga toward allergic rhinitis.

The results of in vivo toxicity, immunomodulatory, and antioxidant effects of C-Phycocyanin suggest that C-phycocyanin is very safe for consumption and possesses substantial antioxidant potential, as well as immunomodulatory activities in Balb/c mice in a dose-dependent manner. C-phycocyanin does not cause acute and subacute toxicity in the tested animal model (male Balb/c mice). The in vivo immunomodulation performance of C-phycocyanin was confirmed in this animal model.

Evidence strength: Preclinical immunomodulatory evidence is consistent; human evidence for Spirulina as a whole food supplement is limited to small RCTs. No purified APC-specific human immunological trials were identified.

7.5 Anti-Aging and Neuroprotective Activity

It has been shown that allophycocyanin increases longevity and reduces the paralysis effect at least in Caenorhabditis elegans. This landmark preclinical observation provides a direct mechanistic investigation of APC (not phycocyanin broadly) in an aging model. This study demonstrated anti-aging activity, longevity, and protective effects of APC against cellular stress in C. elegans, which can lead to the use of this biomolecule in drug development for age-related disorders.

Related neuroprotective effects have been observed with phycobiliproteins broadly: PCB and CPC, frequently coexisting in Spirulina extracts or experimental formulations, have demonstrated beneficial effects in preclinical models of multiple sclerosis, ischemic stroke, and Alzheimer's disease. Reported mechanisms include attenuation of oxidative stress, reduction of neuroinflammation, and preservation of mitochondrial function.

Evidence strength: All neuroprotective and anti-aging evidence for APC specifically is preclinical (invertebrate model organisms). No human data for isolated APC in aging or neurological conditions exist in the available literature.

7.6 Anticancer Activity

Phycobiliproteins are a group of water-soluble proteins with an associated chromophore, responsible for light-harvesting in cyanobacteria. They are divided into four main types — phycoerythrin, phycocyanin, phycoerythrocyanin, and allophycocyanin — characterized according to their structure and light quality absorption. Phycobiliproteins from cyanobacteria have been described as potential bioactive compounds, and recognized as high-valued natural products for biotechnological applications. Moreover, phycobiliproteins have been associated with antioxidant, anticancer, and anti-inflammatory capacities, among others.

The anticancer work relevant to phycobiliproteins includes exploration of phycocyanin (the dominant, most-studied family member) in photodynamic therapy contexts. Phycocyanin shows a wide range of pharmacological effects, with anti-oxidation, anti-cancer, anti-inflammatory activity, photo-induced cytotoxicity, and stimulating the immune system. Phycocyanin plays an antioxidant role in inhibiting hepatic lipid peroxidation and is helpful to liver protection. These findings apply to phycocyanin and, by chemical analogy, to phycobiliproteins including APC, but direct APC-specific human anticancer studies are not established in the literature.

Evidence strength: Preclinical (in vitro and animal) only; no human clinical trials examining APC's anticancer activity in isolation were identified.

7.7 Platelet and Coagulation Effects

A small, double-blind, randomized, placebo-controlled trial (N=24) assessed the impact of aqueous cyanophyta extract from spirulina (2.3 g/day, equivalent to approximately 1 g/day of phycocyanin) on coagulation and platelet activation in adults with chronic pain. After 2 weeks, no significant difference was observed in platelet aggregation, platelet P-selectin expression, serum levels of soluble P-selectin, activated partial thromboplastin time, thrombin clotting time, or fibrinogen activity between the aqueous cyanophyta extract and placebo groups.

Evidence strength: A single small RCT with negative findings; insufficient to draw conclusions about APC's effect on platelet or coagulation function.

8. Body Systems and Health Areas Associated with Allophycocyanin

Oxidative stress and cellular protection: Several bioactivities have been associated with phycobiliproteins, such as antioxidant, antiviral, antimicrobial, and anti-inflammatory properties.
Cardiovascular system: The cardiovascular benefits of Spirulina are primarily the result of its hypolipidemic, antioxidant, and anti-inflammatory activities.
Immune system: Multiple studies investigating the efficacy and potential clinical applications of Spirulina in treating several diseases have been performed, and a few randomized controlled trials and systematic reviews suggest that this alga may improve several symptoms and may even have anticancer, antiviral, and antiallergic effects.
Nervous system / neuroprotection: PCB and CPC, frequently coexisting in Spirulina extracts or experimental formulations, have demonstrated beneficial effects in preclinical models of multiple sclerosis, ischemic stroke, and Alzheimer's disease. Reported mechanisms include attenuation of oxidative stress, reduction of neuroinflammation, and preservation of mitochondrial function.
Aging and longevity (preclinical): An increased mean lifespan of APC-treated (100 μg/ml) worms (wild type) was observed from 16 ± 0.2 days (control) to 20 ± 0.1 days (treated). APC-treated worms also showed improved physiological markers of aging such as the rate of pharyngeal pumping and higher rate of survival against oxidative and thermal stress.
Cancer biology (preclinical): Phycobiliproteins have been associated with antioxidant, anticancer, and anti-inflammatory capacities.

9. Dosage Forms and Reported Dosages

9.1 Commercial Forms

Allophycocyanin is not typically sold as a standalone isolated supplement for general consumers. It is most commonly encountered as a component of whole Spirulina or phycocyanin-rich extracts, available in the following forms:

Dried powder / tablets / capsules: Whole Spirulina biomass marketed as a dietary supplement, in which APC constitutes a fraction of the total phycobiliprotein content alongside C-phycocyanin and phycoerythrin.
Liquid phycocyanin extracts: Partially purified extracts marketed for food coloring or nutraceutical use, graded by purity ratio. The determination of phycocyanin purity is based on the absorbance ratio A620/A280; when A620/A280 ≤ 0.7, phycocyanin is considered food grade; when 0.7 ≤ A620/A280 ≤ 3.9, phycocyanin is considered reagent grade; when A620/A280 ≥ 4.0, phycocyanin is considered analysis level. Allophycocyanin is co-present in most phycocyanin extracts.
High-purity research-grade APC: Used in laboratory diagnostics and flow cytometry; not marketed for dietary supplementation.

One extraction study demonstrated that under optimal maceration conditions (three cycles, 2 h/cycle, 0.1 M phosphate buffer), 55.9 mg/g of biomass of phycocyanin (PC) and 24.9 mg/g of biomass of allophycocyanin (APC) with notable antioxidant capacity were yielded from A. platensis dried biomass. This illustrates that for every gram of dried Spirulina, approximately 24.9 mg of allophycocyanin may be extractable under optimal conditions, meaning it is present at roughly half the abundance of C-phycocyanin.

Phycobiliprotein content analysis revealed concentrations of phycocyanin, allophycocyanin, and phycoerythrin at 84.88 ± 8.29, 53.11 ± 6.21, and 20.25 ± 3.12 μg/mg of dry Spirulina extract, respectively. This ratio demonstrates that allophycocyanin is consistently present at approximately one-half to two-thirds the concentration of C-phycocyanin in Spirulina biomass.

9.2 Dosages Reported in Studies

No published human clinical trials were identified that used isolated purified allophycocyanin as the study intervention. Dosages reported in studies involving APC or APC-containing preparations are as follows:

APC in C. elegans: An increased mean lifespan of APC-treated worms at 100 μg/ml was observed.
Spirulina in allergic rhinitis RCT: A daily dose of Spirulina was used over 12 weeks, as described in Mao et al. (cited within Spirulina in Clinical Practice, PMC3136577); the specific total spirulina dose varied by study and is reported individually in each trial's methods. Individuals with allergic rhinitis were fed daily either with placebo or Spirulina for 12 weeks, with cytokine levels assessed before and after; the study showed that a high dose significantly reduced IL-4 levels by 32%.
Spirulina phycocyanin extract in platelet study: An aqueous cyanophyta extract from Spirulina at 2.3 g/day, equivalent to approximately 1 g/day of phycocyanin, was used in a 2-week trial in 24 adults.
Spirulina in methadone patients: In a double-blind randomized clinical trial, 50 male patients undergoing methadone maintenance therapy were randomly assigned to receive either Spirulina (500 mg twice daily, n=25) or placebo.

Because APC is co-present in all whole-Spirulina dosing protocols, the effective dose of APC delivered in any study using Spirulina biomass cannot be determined without knowing the phycobiliprotein content of the specific batch used.

9.3 Stability Considerations Affecting Dosage Delivery

In its native state, allophycocyanin is sensitive to environmental conditions, particularly high temperatures and pH variations, which can cause the protein to dissociate and lose fluorescent integrity. PC is extremely unstable and sensitive to environmental factors such as light, acid, temperature, and pressure. Phycocyanin is fairly stable at room temperature and under cooled conditions. High color stability has been reported at 0°C and pH 7, with 86% color retention during storage for 45 days. The bioavailability of orally consumed APC in humans — particularly how much survives the acidic gastric environment and is absorbed intact — has not been characterized in published clinical studies.

10. Safety Considerations

10.1 General Safety of Phycobiliproteins and Spirulina

Spirulina is generally considered safe for human consumption, supported by its long history of use as a food source and its favorable safety profile in animal studies. However, rare cases of side-effects in humans have been reported. Quality control in the growth and processing of Spirulina to avoid contamination is mandatory to guarantee the safety of Spirulina products.

In isolated phycobiliprotein research, the specific protein fraction demonstrates good tolerability: the results of in vivo toxicity, immunomodulatory, and antioxidant effects of C-Phycocyanin suggest that C-phycocyanin is very safe for consumption. C-phycocyanin does not cause acute and subacute toxicity in the animal model (male Balb/c mice) studied.

10.2 Cyanotoxin Contamination Risk

A critical and source-documented safety consideration for all cyanobacterial products — including those containing allophycocyanin — is the risk of co-contamination with cyanotoxins. These products generally contain non-toxic cyanobacteria, but the methods of cultivation in natural waters without appropriate quality controls allow contamination by toxin-producer species present in the natural environment. Investigations have examined the presence of total microcystins, seven individual microcystins, anatoxin-a, dihydroanatoxin-a, epoxyanatoxin-a, cylindrospermopsin, saxitoxin, and β-methylamino-L-alanine in commercially available products containing Spirulina or Aphanizomenon flos-aquae.

Cyanobacteria tend to bind heavy metals from the environment, making it necessary to ensure the safety of C-PC for the development of pharmaceutical products with C-PC isolated from naturally collected cyanobacterial biomass. Studies have aimed to determine the content of the most toxic heavy metals — arsenic (As), cadmium (Cd), mercury (Hg), and lead (Pb) — in C-PC isolated from different cyanobacterial biomasses. This is a risk primarily associated with wild-harvested or poorly regulated cultivated material; commercially grown Spirulina produced under controlled conditions in photobioreactors or dedicated open ponds carries a lower but non-zero contamination risk.

Spirulina is subject to regulations, such as requirements for the production process, including ensuring the absence of contaminants (e.g., microcystins, toxic metals, and pathogenic bacteria), labeling, and packaging, in order to ensure its safety and quality.

10.3 Potential Immunomodulatory Caution

Given the demonstrated immunomodulatory activity of phycobiliproteins in preclinical models — including modulation of cytokines such as TNF-α, IL-4, IL-6, and IFN-γ — individuals with autoimmune conditions or those receiving immunosuppressive therapy represent a population in whom the use of high-dose phycocyanin-rich extracts (including APC) has not been adequately studied. No specific drug interaction studies for isolated APC have been identified in the peer-reviewed literature.

10.4 Protein Allergenicity

Phycobilisome proteins, including phycocyanin and allophycocyanin, are recognized by specific IgE antibodies in some sensitized individuals: mass spectrometry identification of immunoreactive spots in patients who were skin prick test positive identified phycocyanin as an allergen component of the Microcystis aeruginosa phycobilisome complex. While this study relates to environmental exposure to bloom-forming cyanobacteria rather than dietary supplementation with cultivated Spirulina, it demonstrates that phycobiliproteins can function as allergens in sensitized individuals.

11. Extraction, Purification, and Analytical Grading

Phycocyanin has been extracted using the freeze-thaw method, ultrasonication, homogenization, and pulse-electric field. Phosphate buffer is the commonly used buffer for extraction. Purification is generally done by a combination of dialysis using ammonium sulfate precipitation combined with column chromatography.

Two C-phycocyanin fractions with purities of 4.66 and 4.25, and an allophycocyanin fraction with a purity of 3.23, were obtained in one purification study. Both C-phycocyanins contain α-subunits of 15.0 kDa and β-subunits of 16.4 kDa, whereas the molecular weight of allophycocyanin is 15.5 kDa.

A two-wavelength spectrophotometric method has been developed to individually determine C-PC and A-PC contents in raw material and complex matrices such as food and supplements. Phycocyanin is extracted with 100 mM phosphate buffer at pH 6 and incubated for 16 h; after centrifugation, the supernatant is filtered and absorbance read at 620 and 650 nm. The absorbance at 652 nm specifically corresponds to allophycocyanin and is used to calculate its concentration in extracts and supplements. The phycocyanin concentration can be calculated based on the absorbance values of A620 and A652, which corresponds to the allophycocyanin.

Phycobiliproteins can command very high prices ranging from 3,000 to 25,000 USD/kg depending on purity. This cost structure means that analytical-grade isolated APC is rarely used in dietary supplement formulations, and consumer products described as containing "phycocyanin" typically contain a mixture that includes allophycocyanin as a minor but measurable co-component.

12. Current Research Limitations and Future Directions

A critical need exists for longer-duration, well-powered trials with standardized Spirulina preparations to translate promising cardiometabolic signals into definitive clinical practice guidelines. This observation applies with even greater force to allophycocyanin specifically, which has received far less clinical research attention than whole Spirulina or even isolated C-phycocyanin.

Key gaps in the evidence base for APC include: (1) the absence of human pharmacokinetic studies characterizing oral bioavailability and systemic distribution of intact APC following ingestion; (2) the lack of clinical trials using purified isolated APC as the intervention; (3) uncertainty regarding which phycobiliprotein species — APC, C-phycocyanin, or their shared chromophore phycocyanobilin — is primarily responsible for observed effects in Spirulina supplementation studies; and (4) limited long-term safety data, particularly in vulnerable populations.

The demonstrated anti-aging activity, longevity, and protective effects of APC against cellular stress in C. elegans can lead to the use of this biomolecule in drug development for age-related disorders. Translation of these findings into mammalian models and ultimately into clinical research represents the next necessary step in the scientific evaluation of allophycocyanin.

References

Health Conditions

Health conditions that Allophycocyanin may help support.

No conditions available.

Body Systems

Body systems that Allophycocyanin may help support.

No body systems available.